{"protocolSection":{"identificationModule":{"nctId":"NCT02562183","orgStudyIdInfo":{"id":"KLK-4002"},"organization":{"fullName":"Techpool Bio-Pharma Co., Ltd.","class":"INDUSTRY"},"briefTitle":"The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein","officialTitle":"The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein"},"statusModule":{"statusVerifiedDate":"2018-01","overallStatus":"UNKNOWN","lastKnownStatus":"ENROLLING_BY_INVITATION","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-08"},"primaryCompletionDateStruct":{"date":"2018-11-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2018-11-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2015-09-10","studyFirstSubmitQcDate":"2015-09-28","studyFirstPostDateStruct":{"date":"2015-09-29","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-01-16","lastUpdatePostDateStruct":{"date":"2018-01-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Techpool Bio-Pharma Co., Ltd.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"In order to reevaluate safety and efficacy of human urinary kallikrein in treating acute cerebral infarction ,a multi-center, open label , single group study was designed. Expect to enroll 60 sites and 2186 subjects. Subjects will receive kallikrein treatment according to real clinical practice (suggest above 14days treatment) and 90 days follow up"},"conditionsModule":{"conditions":["Cerebral Infarction"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":2186,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"kallikrein group","type":"EXPERIMENTAL","description":"Subjects receive kallikrein treatment according to real clinical practice (suggest above 14days treatment),0.15 peptide nucleic acids(PNA), once a day.","interventionNames":["Drug: kallikrein"]}],"interventions":[{"type":"DRUG","name":"kallikrein","description":"Using kallikrein","armGroupLabels":["kallikrein group"],"otherNames":["KLK","Human urinary kallikrein"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants with Adverse Events","timeFrame":"From enrolled to the day 90"}],"secondaryOutcomes":[{"measure":"Cerebral infarction on the National Institute of Health stroke scale","timeFrame":"The day 8,15 and 22 after enrolled"},{"measure":"Recurrence rate of acute cerebral infarction","timeFrame":"From enrolled to the day 90"},{"measure":"Activities of daily living on the Barthel Index","timeFrame":"The day 15,22 and 90 after enrolled"},{"measure":"Patients body status on the Modified Rankin Scale","timeFrame":"The day 15, 22 and 90 after enrolled"},{"measure":"EQ-5D-3L score","timeFrame":"The day 15, 22 and 90 after enrolled"},{"measure":"Evaluation of pharmaceutical economics","timeFrame":"The day 15, 22 and 90 after enrolled"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Acute anterior circulation cerebral infarction diagnosed ≤ 48h;\n2. First time diagnosed or have history of acute anterior circulation cerebral infarction without serious sequelae(mRS=0-2);\n3. Age from 18 to 80 years old;\n4. National Institute of Health stroke scale(NIHSS) from 6 to 25;\n5. Have provided signed written informed consent from the patient or the patient's legal representative.\n\nExclusion Criteria:\n\n1. Brain CT shows cerebral hemorrhage disease: cerebral hemorrhage, subarachnoid hemorrhage, etc.\n2. Transient ischemic attack(TIA);\n3. Serious disturbance of consciousness: Glasgow Coma ScaleGCS（GCS）≤8;\n4. Combined angiotensin-converting enzyme inhibitor(ACEI) less than 5 half-time(according to its instruction), or need to be treated with ACEI;\n5. Cases treated with thrombolysis / stent surgery or expected to be treated with thrombolysis / interventional therapy / stent surgery.\n6. subjects with bleeding disorders at Past or present, laboratory tests: INR \\> 1.5 or APTT \\> 2 times;\n7. subjects with abnormal liver function (ALT/AST \\> 1.5 \\* ULN) and abnormal renal function (Cr\\> normal upper limit);\n8. subjects with history of epilepsy or other serious systemic disease before onset of AIS refused by PI to enroll ;\n9. subjects with cardiogenic stroke or cardiogenic stroke related high-risk factors identified by PI, such as atrial fibrillation, echocardiography or Mural thrombus etc;\n10. subjects diagnosised any malignancy (except basal cell carcinoma) within 5 years prior to the start of the study;\n11. subjects with severe dementia or can't cooperate to evaluate identified by PI;\n12. suffering from severe hypertension and failed to control :systolic blood pressure ≥200mmHg (26.6kPa) or diastolic blood pressure ≥110mmHg (14.6kPa); hypotension: systolic blood pressure\\< 90mmHg and/or diastolic blood pressure\\< 60mmHg\n13. subjects be allergic or intolerant to kallikrein at past;\n14. subjects be pregnant/lactating or possibly and planned pregnant;\n15. subjects be unsuitable for this clinical study identified by PI.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Liying Cui, Doctor","affiliation":"Peking Union Medical College Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Peking Union Medical College Hospital","city":"Beijing","state":"Beijing","zip":"100730","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"NO.2 Hospital XiaMen","city":"Xiamen","state":"Fujian","zip":"361000","country":"China","geoPoint":{"lat":24.47979,"lon":118.08187}},{"facility":"HanDan Central Hospital","city":"Handan","state":"Hebei","zip":"056001","country":"China","geoPoint":{"lat":36.60056,"lon":114.46778}},{"facility":"Harrison International Peace Hospital","city":"Hengshui","state":"Hebei","zip":"053000","country":"China","geoPoint":{"lat":37.73222,"lon":115.70111}},{"facility":"Chenzhou NO.1 People's Hospital","city":"Chenzhou","state":"Hunan","zip":"423000","country":"China","geoPoint":{"lat":25.8,"lon":113.03333}},{"facility":"Affiliated Hospital of Jiangsu University","city":"Zhenjiang","state":"Jiangsu","zip":"212000","country":"China","geoPoint":{"lat":32.21086,"lon":119.45508}},{"facility":"The Fourth Affiliated hospital of Zhejiang University School of Medicine","city":"Yiwu","state":"Zhejiang","zip":"322000","country":"China","geoPoint":{"lat":29.31506,"lon":120.07676}}]},"referencesModule":{"references":[{"pmid":"28265861","type":"DERIVED","citation":"Ni J, Qu J, Yao M, Zhang Z, Zhong X, Cui L; RESK investigators. Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients. Transl Stroke Res. 2017 Aug;8(4):341-346. doi: 10.1007/s12975-017-0527-5. Epub 2017 Mar 6."}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007238","term":"Infarction"}],"ancestors":[{"id":"D000007511","term":"Ischemia"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009336","term":"Necrosis"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000020521","term":"Stroke"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Cerebral Infarction","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000007610","term":"Kallikreins"}],"ancestors":[{"id":"D000003029","term":"Coagulants"},{"id":"D000005303","term":"Fertility Agents, Male"},{"id":"D000005299","term":"Fertility Agents"},{"id":"D000012102","term":"Reproductive Control Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M10328","name":"Kallikreins","asFound":"Homozygous Familial Hypercholesterolemia","relevance":"HIGH"},{"id":"M5949","name":"Coagulants","relevance":"LOW"}],"browseBranches":[{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"Repr","name":"Reproductive Control Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}